Immunovant (IMVT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.68
- Estimate
- -$0.61
- Surprise
- -10.5%
- Score today
- 4.4/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Immunovant (IMVT) reported a wider loss than forecast — diluted EPS of -$0.68 against the -$0.61 estimate (a 10.5% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates IMVT Sell at 4.4/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -10.5% surprise compares with a +3.7% four-quarter average. Next scheduled report: 2026-11-09.
What argues against it
- Concentration risk — Pipeline: IMVT-1402
- Concentration risk — Supplier: Ypsomed AG
- Target reached (-2.9% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $43.73
- Price target
- $51.03
- Stop
- $41.35
- Upside to target
- +16.7%
Risk check: RSI 83 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
IMVT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $9.16B
- P/E (fwd)
- -17.8
- 52-week range
- $14.47–$45.42
- Off 52-week high
- 3.7%
- RSI (14)
- 83
- Volume vs avg
- 0.77×
- Score today
- 4.4/10